St. John's Wort — Research Profile

What the Research Says

The 2008 Cochrane review included 29 trials involving 5,489 people. Tested extracts improved depression response compared with placebo on average, but there was marked heterogeneity, and results were more favorable in trials from German-speaking countries [1]. A later review of 35 studies and 6,993 patients rated the main evidence moderate and emphasized limited data in severe depression and poor reporting of uncommon adverse events [9].

The 2017 review comparing St. John’s wort with SSRIs included 27 trials with 3,808 patients. Response and remission were similar in the studied mild-to-moderate populations, but studies lasted only 4–12 weeks and do not establish long-term safety or effects in people at high suicide risk [8]. A particular extract’s findings cannot be transferred to every retail preparation.

Hyperforin activates the pregnane X receptor and can induce CYP3A4, providing a mechanism for drug interactions [3]. Clinical suitability therefore depends on diagnosis, formulation and a complete medication review. Depression findings do not establish treatment for anxiety alone, general stress or seasonal affective symptoms, and laboratory neurotransmitter mechanisms do not prove those benefits.

Benefits of St. John's Wort

• Depression symptoms — the 2008 Cochrane review included 29 trials with 5,489 participants. Tested extracts outperformed placebo on average, but effect sizes varied by study size and country [1].
• Comparison with antidepressants — reviews reported similar short-term response in mild-to-moderate depression and fewer adverse-event discontinuations. These findings apply to the tested extracts and populations, not all retail products or severe depression [8,9].
• Limits of benefit — the cited depression reviews do not establish treatment for anxiety alone, general stress or seasonal affective symptoms. Improvement in a secondary symptom is not equivalent to evidence for a separate disorder.
• Mechanism and interaction — laboratory work shows hyperforin activates the pregnane X receptor and induces CYP3A4. This helps explain clinically important drug interactions; it is not proof of broader mood benefit [3].

Side Effects and Safety

Safety profile: Caution Needed

Potential Side Effects

• Photosensitivity — increased sensitivity to sunlight and UV radiation; can cause sunburn, rash, or blistering at standard doses in fair-skinned individuals; use sunscreen and avoid prolonged sun exposure
• GI discomfort (nausea, dry mouth, diarrhea) — mild and usually transient; taking with food reduces incidence
• Headache and dizziness can occur; the frequency depends on the preparation and trial.
• Vivid dreams or insomnia — due to neurotransmitter modulation; taking last dose with dinner (not bedtime) may help
• Serotonin syndrome risk when combined with serotonergic drugs — potentially life-threatening; see drug interactions
• Hypomania or mania in individuals with undiagnosed bipolar disorder — St. John's Wort can trigger manic episodes, as can all antidepressants

Drug & Supplement Interactions

• SSRIs and SNRIs (sertraline, fluoxetine, venlafaxine) — NEVER combine; risk of serotonin syndrome, a potentially fatal condition
• Oral contraceptives — St. John's Wort induces CYP3A4, reducing contraceptive hormone levels; breakthrough bleeding and unplanned pregnancies documented
• Warfarin and anticoagulants — CYP induction reduces warfarin levels, decreasing anticoagulation and increasing clot risk
• HIV antiretrovirals (indinavir, efavirenz, nevirapine) — CYP3A4 induction can reduce drug levels by 50-60%, risking treatment failure and viral resistance
• Immunosuppressants (cyclosporine, tacrolimus) — CYP3A4 induction can cause acute organ rejection in transplant patients
• Digoxin — P-glycoprotein induction reduces digoxin levels, potentially causing cardiac arrhythmia management failure
• Other medicines, including some seizure medicines and cancer treatments, may interact through differing pathways. Ask a pharmacist to check each exact drug rather than assuming a shared CYP3A4 mechanism.